12/12
11:15 am
qttb
Rating for QTTB
Medium
Report
Rating for QTTB
12/12
11:15 am
qttb
Rating for QTTB
Medium
Report
Rating for QTTB
12/12
10:07 am
qttb
Rating for QTTB
High
Report
Rating for QTTB
12/12
10:07 am
qttb
Rating for QTTB
High
Report
Rating for QTTB
12/11
11:05 am
qttb
Q32 Bio Inc. (NASDAQ: QTTB) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.
High
Report
Q32 Bio Inc. (NASDAQ: QTTB) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.
12/11
11:05 am
qttb
Q32 Bio Inc. (NASDAQ: QTTB) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.
High
Report
Q32 Bio Inc. (NASDAQ: QTTB) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.
12/11
10:43 am
qttb
Q32 Bio downgraded to Neutral from Buy at Guggenheim
High
Report
Q32 Bio downgraded to Neutral from Buy at Guggenheim
12/11
10:43 am
qttb
Q32 Bio downgraded to Neutral from Buy at Guggenheim
High
Report
Q32 Bio downgraded to Neutral from Buy at Guggenheim
12/11
08:25 am
qttb
Rating for QTTB
High
Report
Rating for QTTB
12/11
08:25 am
qttb
Rating for QTTB
High
Report
Rating for QTTB
12/11
08:21 am
qttb
Q32 Bio Inc. (NASDAQ: QTTB) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $22.00 price target on the stock, down previously from $90.00.
High
Report
Q32 Bio Inc. (NASDAQ: QTTB) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $22.00 price target on the stock, down previously from $90.00.
12/11
08:21 am
qttb
Q32 Bio Inc. (NASDAQ: QTTB) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $22.00 price target on the stock, down previously from $90.00.
High
Report
Q32 Bio Inc. (NASDAQ: QTTB) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $22.00 price target on the stock, down previously from $90.00.
12/11
08:21 am
qttb
Q32 Bio Inc. (NASDAQ: QTTB) had its "market perform" rating re-affirmed by analysts at Leerink Partners. They now have a $9.00 price target on the stock, down previously from $68.00.
High
Report
Q32 Bio Inc. (NASDAQ: QTTB) had its "market perform" rating re-affirmed by analysts at Leerink Partners. They now have a $9.00 price target on the stock, down previously from $68.00.
12/11
08:21 am
qttb
Q32 Bio Inc. (NASDAQ: QTTB) had its "equal weight" rating re-affirmed by analysts at Wells Fargo & Company. They now have a $16.00 price target on the stock, down previously from $95.00.
High
Report
Q32 Bio Inc. (NASDAQ: QTTB) had its "equal weight" rating re-affirmed by analysts at Wells Fargo & Company. They now have a $16.00 price target on the stock, down previously from $95.00.
12/11
07:55 am
qttb
Rating for QTTB
High
Report
Rating for QTTB
12/11
07:55 am
qttb
Rating for QTTB
High
Report
Rating for QTTB
12/11
06:55 am
qttb
Rating for QTTB
High
Report
Rating for QTTB
12/11
06:15 am
qttb
Rating for QTTB
High
Report
Rating for QTTB
12/11
06:15 am
qttb
Rating for QTTB
High
Report
Rating for QTTB
12/11
06:15 am
qttb
Q32 Bio downgraded to Market Perform from Outperform at Leerink
High
Report
Q32 Bio downgraded to Market Perform from Outperform at Leerink
12/11
05:42 am
qttb
Q32 Bio downgraded to Outperform from Strong Buy at Raymond James
High
Report
Q32 Bio downgraded to Outperform from Strong Buy at Raymond James
12/11
05:42 am
qttb
Q32 Bio downgraded to Outperform from Strong Buy at Raymond James
High
Report
Q32 Bio downgraded to Outperform from Strong Buy at Raymond James
12/10
09:14 pm
qttb
Q32 Bio downgraded to Equal Weight from Overweight at Wells Fargo
High
Report
Q32 Bio downgraded to Equal Weight from Overweight at Wells Fargo
12/10
09:14 pm
qttb
Q32 Bio downgraded to Equal Weight from Overweight at Wells Fargo
High
Report
Q32 Bio downgraded to Equal Weight from Overweight at Wells Fargo
12/6
08:13 am
qttb
Q32 Bio Inc. (NASDAQ: QTTB) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating and a $64.00 price target on the stock.
Medium
Report
Q32 Bio Inc. (NASDAQ: QTTB) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating and a $64.00 price target on the stock.